197 related articles for article (PubMed ID: 35361262)
21. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
[TBL] [Abstract][Full Text] [Related]
22. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
Pang B; Durso MB; Hamilton RL; Nikiforova MN
Diagn Mol Pathol; 2013 Mar; 22(1):28-34. PubMed ID: 23370430
[TBL] [Abstract][Full Text] [Related]
23. Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma.
Adachi JI; Shirahata M; Suzuki T; Mishima K; Uchida E; Sasaki A; Nishikawa R
Brain Tumor Pathol; 2021 Jul; 38(3):201-209. PubMed ID: 34128111
[TBL] [Abstract][Full Text] [Related]
24. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
[TBL] [Abstract][Full Text] [Related]
25. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
26. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
27. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
[TBL] [Abstract][Full Text] [Related]
28. Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.
Ge J; Liu MY; Li L; Deng Q; Liu F; Luo Y; Wang L; Yao G; Zhu D; Lu H; Liang M; Deng S; Zhou R; Luo T
Int J Clin Exp Pathol; 2020; 13(2):230-238. PubMed ID: 32211103
[TBL] [Abstract][Full Text] [Related]
29. Molecular Pathology of Gliomas.
Galbraith K; Snuderl M
Surg Pathol Clin; 2021 Sep; 14(3):379-386. PubMed ID: 34373090
[TBL] [Abstract][Full Text] [Related]
30. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
31. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
32. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.
Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M
Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231
[TBL] [Abstract][Full Text] [Related]
33. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
[TBL] [Abstract][Full Text] [Related]
34. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
35. [Practical approach to molecular pathology of central nervous system tumours].
Vida L; Horváth B; Kajtár B
Magy Onkol; 2023 Dec; 67(4):304-313. PubMed ID: 38109509
[TBL] [Abstract][Full Text] [Related]
36. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
[TBL] [Abstract][Full Text] [Related]
37. Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification.
Akagi Y; Yoshimoto K; Hata N; Kuga D; Hatae R; Amemiya T; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
Brain Tumor Pathol; 2018 Apr; 35(2):81-89. PubMed ID: 29569163
[TBL] [Abstract][Full Text] [Related]
38. IDH clonal heterogeneity segregates a subgroup of non-1p/19q codeleted gliomas with unfavourable clinical outcome.
Luo S; Zhu S; Liao J; Zhang Y; Hou X; Luo T; Zhao E; Xu J; Pang L; Liang X; Xiao Y; Li X
Neuropathol Appl Neurobiol; 2021 Apr; 47(3):394-405. PubMed ID: 33098109
[TBL] [Abstract][Full Text] [Related]
39. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Weller M; Reifenberger G
Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
[TBL] [Abstract][Full Text] [Related]
40. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
